Viking Therapeutics Inc VKTX
π Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-04-29 |
| Shares Out. | 116,650,000 |
| Website | vikingtherapeutics.com/ β |
| Phone | 18009279800 |
| Employees | 59 |
| Net Income | -$128.0M |
| Total Assets | $521.9M |
| Total Liabilities | $113.6M |
| Equity | $408.3M |
About Viking Therapeutics Inc
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Viking Therapeutics Inc is a publicly traded company under the ticker symbol VKTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
π Analyst Ratings
26 analysts (2026-07-01)

